Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-9

  Uhler, Lauren M ^a   Kumarasamy, Nagalingeswaran ^d   Mayer, Kenneth H ^e   Saxena, Anjali ^a   Losina, Elena ^b,c   Muniyandi, Malaisamy ^f   Stoler, Adam W ^a   Lu, Zhigang ^a   Walensky, Rochelle P ^a,b,c   Flanigan, Timothy P ^e   Bender, Melissa A ^g   Freedberg, Kenneth A ^a,b   Swaminathan, Soumya ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^e BROWN UNIVERSITY   (United States)

^f INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INDIA; INFECTION RISK; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT REFERRAL; PATIENT SELECTION; PREVALENCE; SCREENING TEST; SURVIVAL TIME; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; COST BENEFIT ANALYSIS; ECONOMICS; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED; TUBERCULOSIS;

EID: 77958578199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012747     Document Type: Article

References (59)

1. Steinbrook R (2007) Tuberculosis and HIV in India. N Engl J Med 356: 1198-1199.
2. RNTCP TB India 2009: RNTCP Status Report. In: Central TB Division DGoHS, editor. New Delhi.
3. UNAIDS/WHO (2007) 2007 AIDS Epidemic Update. UNAIDS.
4. Reid A, Scano F, Getahun H, Williams B, Dye C, et al. (2006) Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 6: 483-495.
5. Raizada N, Chauhan LS, Babu BS, Thakur R, Khera A, et al. (2009) Linking HIV-infected TB patients to cotrimoxazole prophylaxis and antiretroviral treatment in India. PLoS ONE 4: e5999.
6. Sharma A, Wanchu A, Bansal V, Singh S, Varma S (2007) Improvement in CD 4 counts in HIV positive patients treated with HAART and antitubercular drugs: an observational study from North India. Indian J Pathol Microbiol 50: 905-907.
7. NACO (October 2009) National Framework for Joint HIV/TB Collaborative Activities. In: Organization CTDaNAC, editor. New Dehli: Ministry of Health and Family Welfare, Government of India.
8. WHO (2009) WHO Report 2009 - Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing.
9. RNTCP TB India 2008: RNTCP Status Report. In: Central TB Division DGoHS, editor. New Delhi.
10. Raizada N, Chauhan LS, Khera A, Sokhey J, Wares DF, et al. (2008) HIV seroprevalence among tuberculosis patients in India, 2006-2007. PLoS ONE 3: e2970.
11. RNTCP (2010) TB India 2010: RNTCP Status Report.
12. Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, et al. (2007) Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 21 Suppl 4: S117-128.
13. Bender MA, Kumarasamy N, Mayer KH, Wang B, Walensky RP, et al. (2010) Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India. Clin Infect Dis 50: 416-425.
14. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings-the case of Coĉte d'Ivoire. N Engl J Med 355: 1141-1153.
15. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, et al. (2005) Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 19: 1299-1308.
16. Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, et al. (2008) Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 197: 1324-1332.
17. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA, et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157-166.
18. Gold RM, Siegel EJ, Russell BL, Weinstein CM (1996) Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press.
19. Vijay S, Swaminathan S, Vaidyanathan P, Thomas A, Chauhan LS, et al. (2009) Feasibility of provider-initiated HIV testing and counselling of tuberculosis patients under the TB control programme in two districts of South India. PLoS ONE 4: e7899.
20. WHO (2001) Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization.
21. IMF (October 2009) World Economic Outlook Database. International Monetary Fund.
22. Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, et al. (1997) Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
23. Wang B, Kumarasamy N, Divi N, Cecelia AJ, Mayer KH, et al. (2006) Incidence of opportunistic infections (OIs) within specific CD4 strata in HIVinfected patients in Southern India [abstract WePe0279]. XVI International AIDS Conference: Toronto, Canada.
24. Zhou J, Kumarasamy N, Ditangco R, Kamarulzaman A, Lee CK, et al. (2005) The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 38: 174-179.
25. NACO (2007) Antiretroviral therapy guidelines for adults and adolescents including post-exposure prophylaxis. New Delhi: Ministry of Health & Family Welfare, Government of India.
26. WHO (2006) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach.
27. National AIDS Control Organization (2007) Guidelines for Prevention and Management of Common Opportunistic Infections/Malignancies among HIVInfected Adult and Adolescent. In: Ministry of Health & Family Welfare GoI, editor. New Delhi.
28. WHO (2008) Global Tuberculosis Control: Surveillance, Planning, Financing. In: Organization WH, editor. Geneva.
29. Swaminathan S, Deivanayagam CN, Rajasekaran S, Venkatesan P, Padmapriyadarsini C, et al. (2008) Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy. Natl Med J India 21: 3-8.
30. Dewan PK, Gupta D, Williams BG, Thakur R, Bachani D, et al. (2010) National estimate of HIV seroprevalence among tuberculosis patients in India. Int J Tuberc Lung Dis 14: 247-249.
31. WHO (2008) Global Tuberculosis Control: Surveillance, Planning, Financing. Geneva.
32. Tuboi SH, Brinkhof MW, Egger M, Stone RA, Braitstein P, et al. (2007) Discordant responses to potent antiretroviral treatment in previously naive HIV-1-infected adults initiating treatment in resource-constrained countries: the antiretroviral therapy in low-income countries (ART-LINC) collaboration. J Acquir Immune Defic Syndr 45: 52-59.
33. Anglaret X, Cheĉne G, Attia A, Touré S, Lafont S, et al. (1999) Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Coĉte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 353: 1463-1468.
34. Homan RK, Ganesh AK, Duraisamy P, Castle C, Sripriya M, et al. (2000) Economic Analyses of YRG CARE Services: implications for program sustainability. Research Triangle Park, NC, USA: Family Health International.
35. NACO (2010) Care, Support, and Treatment: National AIDS Control Programme, Phase-III, India.
36. Management Sciences for Health (2009) The International Drug Price Indicator Guide.
37. Muniyandi M, Rajeswari R, Balasubramanian R (2006) Estimating provider cost for treating patients with tuberculosis under Revised National Tuberculosis Control Programme (RNTCP). Indian J Tuberc. pp 12-17.
38. Tamil Nadu State AIDS Control Society (2010) Health & Family Welfare Department, Government of Tamil Nadu.
39. Khan FA, Minion J, Pai M, Royce S, Burman W, et al. (2010) Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and metaanalysis. Clin Infect Dis 50: 1288-1299.
40. WHO (2007) Guidance on provider-initiated HIV testing and counselling in health facilities. HIV/AIDS Programme. Geneva: World Health Organization.
41. NACO (2010) National AIDS Control Programme: Response to the HIV Epidemic in India.
42. Sogarwal R, Bachani D (2009) Are persons living with HIV timely accessing ART services in India? J Indian Med Assoc 107: 228-290,307.
43. Williams BG, Granich R, Chauhan LS, Dharmshaktu NS, Dye C (2005) The impact of HIV/AIDS on the control of tuberculosis in India. Proc Natl Acad Sci U S A 102: 9619-9624.
44. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. Aids 23: 1717-1725.
45. Lawn SD, Kranzer K, Wood R (2009) Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 30: 685-699,viii.
46. Bassett IV, Regan S, Chetty S, Giddy J, Uhler LM. Who starts antiretroviral therapy in Durban, South Africa? not everyone who should. AIDS 24 Suppl 1: S37-44.
47. Liechty CA (2005) The evolving role of HIV counseling and testing in resourcelimited settings: HIV prevention and linkage to expanding HIV care access. Curr Infect Dis Rep 7: 154-158.
48. Sri Krishnan AK, Hendriksen E, Vallabhaneni S, Johnson SL, Raminani S, et al. (2007) Sexual behaviors of individuals with HIV living in South India: a qualitative study. AIDS Education and Prevention 19: 334-345.
49. The Voluntary HIV-1 Counseling and Testing Efficacy Study Group (2000) Efficacy of voluntary HIV-1 counselling and testing in individuals and couples in Kenya, Tanzania, and Trinidad: a randomised trial. Lancet 356: 103-112.
50. Allen S, Meinzen-Derr J, Kautzman M, Zulu I, Trask S, et al. (2003) Sexual behavior of HIV discordant couples after HIV counseling and testing. Aids 17: 733-740.
51. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD (2008) HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav 12: 363-373.
52. WHO (2009) Global Tuberculosis Control: a short update to the 2009 report. In: Organization WH, editor.
53. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
54. Marks G, Crepaz N, Senterfitt JW, Janssen RS (2005) Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr 39: 446-453.
55. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, et al. (2006) Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. Aids 20: 85-92.
56. Rajeswari R, Balasubramanian R, Muniyandi M, Geetharamani S, Thresa X, et al. (1999) Socio-economic impact of tuberculosis on patients and family in India. Int J Tuberc Lung Dis 3: 869-877.
57. WHO (2010) Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010 revision.
58. WHO (2008) WHO Three I's Meeting: Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT), and TB Infection Control (IC) for people living with HIV. Genevea: WHO HIV/AIDS and TB Department.
59. Sadacharam K, Gopi PG, Chandrasekaran V, Eusuff SI, Subramani R, et al. (2007) Status of smear-positive TB patients at 2-3 years after initiation of treatment under a DOTS programme. Indian J Tuberc 54: 199-203.